Strata Skin Sciences (FRA:E2O) ROCE %: 22.81% (As of Dec. 2025)

What is Strata Skin Sciences ROCE %?

Strata Skin Sciences FRA:E2O 38 ROCE % is 22.81% as of Dec. 2025. GuruFocus rates FRA:E2O with a GF Score™ of 38/100 and a GF Value™ of €58.84. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Strata Skin Sciences's annualized ROCE % for the quarter that ended in Dec. 2025 was 22.81%.

Strata Skin Sciences (FRA:E2O) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Strata Skin Sciences ROCE % Related Terms

Strata Skin Sciences ROCE % Historical Data

* Premium members only.

The historical data trend for Strata Skin Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strata Skin Sciences ROCE % Chart

Strata Skin Sciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-7.89

-12.93

-26.59

-32.47

-30.80

Strata Skin Sciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
ROCE %	Get a 7-Day Free Trial															-72.89	-37.65	-43.05	-27.51	22.81

38GF Score

Strata Skin Sciences Inc FRA:E2O

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Strata Skin Sciences ROCE % Calculation

Strata Skin Sciences's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-3.664	/	( ( (33.356 - 12.793)	+	(26.065 - 22.837) )	/ 2 )
	=	-3.664	/	( (20.563	+	3.228)	/ 2 )
	=	-3.664	/	11.8955
	=	-30.80 %

Strata Skin Sciences's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2025 )		(Q: Sep. 2025 )		(Q: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2025 )		(Q: Sep. 2025 )		(Q: Dec. 2025 )
	=	1.892	/	( ( (26.171 - 12.808)	+	(26.065 - 22.837) )	/ 2 )
	=	1.892	/	( ( 13.363	+	3.228 )	/ 2 )
	=	1.892	/	8.2955
	=	22.81 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 22.81% mean?

Strata Skin Sciences (FRA:E2O) has a ROCE % of 22.81% as of Dec. 2025.

Is Strata Skin Sciences' ROCE % too high?

Strata Skin Sciences' current ROCE % is 22.81%. The Medical Devices & Instruments industry median ROCE % is 2.23. Strata Skin Sciences' value of 22.81% is 922.9% above this industry median. Overall, Strata Skin Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.

How does Strata Skin Sciences' ROCE % compare to IRME and NUMD?

Strata Skin Sciences' ROCE % of 22.81% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Strata Skin Sciences' value of 22.81% is 922.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strata Skin Sciences's current ROCE % of 22.81% is 922.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strata Skin Sciences's current ROCE % is 22.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Strata Skin Sciences stock overvalued right now?

Strata Skin Sciences (FRA:E2O) has a current ROCE % of 22.81%. The stock's GF Value™ is €58.84, compared to a current price of €3.76 — trading 93.6% below its estimated fair value. The current ROCE % is 22.81% and 922.9% above the Medical Devices & Instruments industry median of 2.23. Strata Skin Sciences' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Strata Skin Sciences (FRA:E2O), the current ROCE % is 22.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strata Skin Sciences (FRA:E2O) Overvalued in 2026?

Based on GuruFocus' analysis, Strata Skin Sciences stock appears to be undervalued. The current stock price of €3.76 is trading 93.6% below its estimated GF Value™ of €58.84.

Key valuation signals for FRA:E2O:

ROCE %: 22.81%
GF Value™: €58.84 vs. price of €3.76 (93.6% below fair value)
GF Score™: 38/100 with 5 warning signs
Industry Position: 922.9% above the Medical Devices & Instruments median

No single metric tells the full story. See the FRA:E2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Strata Skin Sciences Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies IRME NUMD WOK ESMC PFSA ODYY NUWE BJDX VYCO VTAK ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges SSKN:USA

Address 5 Walnut Grove Drive, Suite 140, Horsham, PA, USA, 19044

Website https://www.strataskinsciences.com

Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.

38GF Score

Get the complete analysis for FRA:E2O

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.76

Price

€58.84

GF Value

View FRA:E2O Analysis

See ROCE % data for all stocks →